The first annual workshop for preclinical and clinical development of radiosensitizers took place at the National Cancer Institute on August 8-9, 2012. Radiotherapy is one of the most commonly applied and effective oncologic treatments for solid tumors. It is well recognized that improved clinical efficacy of radiotherapy would make a substantive impact in clinical practice and patient outcomes. Advances in genomic technologies and high-throughput drug discovery platforms have brought a revolution in cancer treatment by providing molecularly targeted agents for various cancers. Development of predictive biomarkers directed toward specific subsets of cancers has ushered in a new era of personalized therapeutics. The field of radiation oncology stands to gain substantial benefit from these advances given the concerted effort to integrate this progress into radiation therapy. This workshop brought together expert clinicians and scientists working in various disease sites to identify the exciting opportunities and expected challenges in the development of molecularly targeted agents in combination with radiation therapy.
|Number of pages||8|
|Journal||Journal of the National Cancer Institute|
|Publication status||Published - 2013 May 15|
Bibliographical noteFunding Information:
Steven H. Lin: the American Society for Radiation Oncology (ASTRO) Junior Faculty Fellowship Award, the University of Texas MD Anderson Cancer Center, and the National Cancer Institute Cancer Center Support Grant CA016672; Quynh Le: 1R01CA161585-01A1, 1R21DE021167A1-01; Theodore S. Lawrence: R01CA138723, P30CA130810.
All Science Journal Classification (ASJC) codes
- Cancer Research